Publikace na Lékařská fakulta v Hradci Králové |
2009
Abstrakt
In this international, multicenter, randomized, double-blind, prospective trial involving 2776 maintenance haemodialysis patients, authors randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. Median follow-up period was 3.8 years.
The initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.